Wick Capital Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$598K Buy
651
+47
+8% +$47.6K 0.11% 84
2025
Q4
$649K Buy
604
+137
+29% +$131K 0.12% 74
2025
Q3
$357K Sell
467
-1,317
-74% -$980K 0.09% 89
2025
Q2
$364K Buy
1,784
+1,247
+232% +$969K 0.09% 80
2025
Q1
$444K Buy
537
+66
+14% +$54.9K 0.13% 70
2024
Q4
$364K Buy
471
+82
+21% +$67.9K 0.11% 68
2024
Q3
$344K Buy
389
+9
+2% +$8.09K 0.11% 57
2024
Q2
$344K Buy
+380
New +$304K 0.12% 55

Other funds holding LLY

Wick Capital Partners's LLY Position: Q1 2026 in Review

Wick Capital Partners increased its Eli Lilly (LLY) stake by 7.8% in Q1 2026, buying an estimated $47.6K and bringing the position to 651 shares worth $598K. The position accounts for 0.11% of the portfolio, ranked #84.

Wick Capital Partners first reported a position in LLY in Q2 2024 and has held it in 8 quarters since. The position peaked at $649K in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Wick Capital Partners held 651 shares of Eli Lilly worth $598K as of Q1 2026.
  • Wick Capital Partners bought 47 Eli Lilly shares in Q1 2026, an estimated $47.6K.
  • Eli Lilly made up 0.11% of Wick Capital Partners's portfolio in Q1 2026, its #84 holding.
  • Wick Capital Partners first reported a position in Eli Lilly in Q2 2024 and has held it in 8 quarters since.
  • Wick Capital Partners's Eli Lilly position peaked at $649K in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Wick Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.